Cofactor Genomics, Inc., a clinical-stage company focused on bridging the precision medicine gap through RNA decoding, today announced the validation and launch of OncoPrism®-NSCLC, an RNA-based diagnostic test designed to predict response to immune checkpoint inhibitors (ICI) in patients with non-small cell lung cancer (NSCLC).
The launch of OncoPrism-NSCLC follows the recent Medicare coverage approval for Cofactor’s OncoPrism-HNSCC test. Both tests leverage Cofactor’s proprietary Health Expression Models, which combine RNA expression data with machine learning to accurately predict how patients will respond to ICI treatments.
“OncoPrism-NSCLC dramatically increases the number of patients who can benefit from OncoPrism testing, as NSCLC represents the largest group of cancer patients being treated with ICIs,” said Dr. Jarret Glasscock, CEO of Cofactor Genomics. “This launch is a key step in our mission to bring precision medicine to all cancer patients.”
OncoPrism-NSCLC Validation and Clinical Impact
OncoPrism-NSCLC uses pre-treatment tumor biopsies to predict how well patients will respond to ICI treatments and is processed in Cofactor’s CAP-accredited, CLIA-certified laboratory. The test’s validation was based on data from patients in the PREDAPT trial (NCT04510129), which includes 12 clinical sites. In total, 17 sites are participating in the ongoing trial. The OncoPrism-NSCLC predictions were found to be strongly correlated with patient responses to ICIs, both as single-agent therapies and in combination with chemotherapy.
Beyond NSCLC and head and neck squamous cell carcinoma (HNSCC), Cofactor’s national PREDAPT clinical trial also evaluates OncoPrism in nine other cancer types, including colorectal, breast, cervical, liver, kidney, esophageal, and bladder cancers.
About Cofactor Genomics
Cofactor Genomics is a clinical-stage diagnostics company using RNA decoding to bridge the precision medicine gap in cancer care. The company’s proprietary Health Expression Models (HEMs), which combine RNA expression with advanced machine learning, provide a more comprehensive and actionable approach than traditional gene mutation panels. Cofactor’s PRISM database of HEMs transforms vast amounts of RNA data into high-dimensional models that predict disease behavior and therapeutic responses.
Cofactor’s work in RNA modeling has been recognized as breakthrough research in cancer and published in leading journals such as The Journal of ImmunoTherapy of Cancer and The Journal of Molecular Diagnostics, with additional recognition from Nature Scientific Reports. The company is partnered with 38 healthcare systems, covering 20% of U.S. healthcare. Cofactor’s OncoPrism tests are CAP/CLIA-validated and Medicare-approved, further cementing the company’s role in advancing precision oncology.
